Neoleukin Therapeutics

Neoleukin Therapeutics: Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Infectious Disease, Oncology
Public, USA
Market Cap
100MM - 500MM
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Jonathan G. Drachman, Pres/CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 9.73 4,117,569 42.82 13F 3/31/21
Baker Bros. Advisors LP 9.03 3,824,000 39.77 Stakes 5/11/21
Ecor1 Capital LLC 7.38 3,122,704 32.48 13F 3/31/21
Pictet Asset Management Ltd. 4.74 2,008,212 20.89 13F 3/31/21
BlackRock Fund Advisors 3.81 1,612,493 16.77 13F 3/31/21
State Street Corp. 3.73 1,579,068 16.42 13F 3/31/21
The Vanguard Group, Inc. 3.57 1,512,898 15.73 Funds 4/30/21
Boxer Capital LLC 3.55 1,501,058 15.61 13F 3/31/21
Vanguard Group, Inc. (Subfiler) 3.37 1,426,777 14.84 13F 3/31/21
Point72 Asset Management LP (Old) 3.09 1,308,600 13.61 13F 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.